Business Context and Reporting Period
Company: Recursion Pharmaceuticals, Inc. (RXRX)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Recursion is a clinical-stage TechBio company utilizing an AI-native operating system (Recursion OS) to decode biology and accelerate drug discovery. The company operates as a single segment, focusing on wholly-owned clinical programs and strategic partnerships with major pharmaceutical companies. In 2025, the company achieved its first AI-enabled clinical proof of concept with REC-4881 for Familial Adenomatous Polyposis (FAP).
Key Financial Metrics
| Metric (in millions) | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenue | $74.7 | $58.8 | +26.9% |
| Net Loss | $(644.8) | $(463.7) | +39.1% (wider loss) |
| Operating Loss | $(648.1) | $(479.0) | +35.3% |
| Research & Development Expense | $475.3 | $314.4 | +51.2% |
| Cash, Cash Equivalents & Restricted Cash | $753.9 | $603.0 | +25.0% |
| Accumulated Deficit | $(2.1 billion) | $(1.4 billion) | N/A |
Liquidity: As of December 31, 2025, the company held $753.9 million in cash and cash equivalents. Management believes this is sufficient to fund operations for at least the next 12 months. The company raised approximately $528.9 million in net proceeds from Class A common stock issuances in 2025.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 26.9% to $74.7 million, primarily driven by the full-year inclusion of the Sanofi collaboration (acquired via Exscientia in late 2024) and milestone payments from Roche and Genentech. This was partially offset by timing differences in Roche revenue recognition.
- Expense Increase: Operating expenses rose significantly, with R&D increasing 51.2% to $475.3 million. Key drivers included the full-year consolidation of Exscientia operations, $49.9 million in Tempus data record purchases, and $22.8 million in acquired in-process research and development (IPR&D).
- Partnership Milestones: The company received $37.0 million in milestone payments in 2025, including a $30 million acceptance fee from Roche/Genentech for a Microglia Map and a $4 million milestone from Sanofi.
- Portfolio Optimization: In May 2025, the company streamlined its portfolio, discontinuing or seeking partners for REC-2282, REC-994, and REC-3964 to focus capital on high-impact programs like REC-4881 and REC-617.
Guidance, Outlook, and Risks
Management Commentary & Outlook
Management views 2025 as an inflection point where the AI platform translated into clinical reality. The outlook for 2026 focuses on:
- REC-4881 (FAP): Engaging the FDA in H1 2026 to define a registration pathway following positive Phase 1b/2 data showing durable polyp burden reduction.
- REC-617 (Oncology): Reporting early combination safety and PK data in 2027; advancing Phase 2 expansion in ovarian cancer.
- REC-1245 (Oncology): Reporting early Phase 1 safety and PK data in H1 2026.
- Capital Discipline: The company has reduced projected cash burn while maintaining investment in high-impact programs and platform capabilities.
Key Risks and Contingencies
- Internal Control Weaknesses: The company identified material weaknesses in internal control over financial reporting related to the Exscientia acquisition (ineffective processes and IT general controls). These remain unremediated as of December 31, 2025, though remediation efforts are underway.
- Capital Requirements: As a clinical-stage company with no approved products, Recursion expects to incur continued losses and will require substantial additional funding to advance its pipeline and commercialize products.
- Regulatory & Clinical Risk: Success depends on the ability to obtain regulatory approval for drug candidates, which is uncertain. Clinical trials may fail to demonstrate efficacy or safety.
- Partnership Dependency: A significant portion of revenue and future value is derived from collaborations (Roche, Sanofi, Bayer, Merck). Failure of these partners to prioritize or successfully develop programs could impact financial results.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $753.9 million cash balance against the projected burn rate, considering the need for future capital raises.
- REC-4881 Clinical Data: Review the durability of the polyp burden reduction data in the TUPELO study and the FDA's response to the upcoming registration path engagement.
- Internal Control Remediation: Monitor progress on remediating the material weaknesses in internal controls over financial reporting identified in the Exscientia integration.
- Partnership Milestones: Track the achievement of future milestones with Sanofi and Roche/Genentech, which are critical for near-term revenue recognition.
- Portfolio Prioritization: Assess the impact of discontinued programs (REC-2282, REC-994, REC-3964) on the overall pipeline depth and potential future licensing opportunities.